Abstract

BackgroundClopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively. However these are not based on orthopaedic patients. We therefore decided to survey current orthopaedic practice to see whether this complied with available clinical data.MethodA questionnaire was sent to all orthopaedic consultants in Scotland.Four haematology departments, and the manufacturers, were contacted to ask for their recommendations, and a database search was performed.Results140 questionnaires were sent with a 60.7% response. 84.7% of respondents have encountered patients on clopidogrel. Of those, 13.9% did not routinely stop it, and 86.1% stopped it 5–21 days pre-operatively (47.2% at 7 days).45.9% had a unit policy on stopping clopidogrel, and the majority (69.4%) did not consult their haematology department prior to instituting their policy.Increased peri-operative bleeding was the most reported complication (22.6%). However this was only noted in those who stopped clopidogrel greater-than 7 days pre-operatively.Haematology advice ranged from continuing clopidogrel peri-operatively to stopping it 7 days pre-operatively and starting low-molecular-weight-heparin for thrombo-prophylaxis. The manufacturers suggested stopping clopidogrel 7 days pre-operatively. An internet search did not reveal any data on the effect of clopidogrel peri-operatively in orthopaedic patients.DiscussionRecommendations on stopping clopidogrel have evolved from studies conducted on patients undergoing cardio-thoracic surgery. There is no data available on the effect of clopidogrel in orthopaedic practice. Our survey indicates that increased bleeding has not been found in patients who continue clopidogrel peri-operatively.Almost half of respondents complied with current recommendations, stopping clopidogrel 7 days pre-operatively. However there remains a lack of consensus amongst orthopaedic surgeons.Currently elective patients should stop clopidogrel 7 days pre-operatively, and emergency patients should stop clopidogrel on admission, however their operation should not be delayed due to clopidogrel usage.

Highlights

  • Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease

  • An internet search did not reveal any data on the effect of clopidogrel peri-operatively in orthopaedic patients

  • Clopidogrel bisulfate (Plavix®) is an antiplatelet agent that is used in the secondary prevention of ischaemic events in patients with ischaemic heart disease or peripheral vascular disease that are intolerant of aspirin, or in those who require additional antiplatelet therapy in combination with aspirin [1]

Read more

Summary

Introduction

Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively These are not based on orthopaedic patients. Clopidogrel bisulfate (Plavix®) is an antiplatelet agent that is used in the secondary prevention of ischaemic events in patients with ischaemic heart disease or peripheral vascular disease that are intolerant of aspirin, or in those who require additional antiplatelet therapy in combination with aspirin [1]. Atherosclerotic disease of both peripheral and central arteries is extremely common in the British population [2]. There is no SIGN recommendation for patients taking clopidogrel

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.